🔎 Trials Near Me

Beranda › Leukemia Mieloid Akut › Nebraska › Omaha

Uji klinis Leukemia Mieloid Akut di Omaha, NE

10 studi untuk Leukemia Mieloid Akut mencari peserta di lokasi sekitar Omaha (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Menerima pesertaStudi observasionalSukarelawan sehat diterima
  • Alegent Health Immanuel Medical Center, Omaha
  • Alegent Health Bergan Mercy Medical Center, Omaha
  • Alegent Health Lakeside Hospital, Omaha
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Menerima pesertaFase 2
  • Nebraska Medicine-Village Pointe, Omaha
  • University of Nebraska Medical Center, Omaha
  • Nebraska Medicine-Bellevue, Bellevue · 9 mi jauhnya
Usia 18 hingga 59 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05554393

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Menerima pesertaFase 2
  • Nebraska Medicine-Village Pointe, Omaha
  • University of Nebraska Medical Center, Omaha
  • Nebraska Medicine-Bellevue, Bellevue · 9 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05564390

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Menerima pesertaFase 2
  • Nebraska Medicine-Village Pointe, Omaha
  • University of Nebraska Medical Center, Omaha
  • Nebraska Medicine-Bellevue, Bellevue · 9 mi jauhnya
Usia 18 hingga 59 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Menerima pesertaFase 3
  • Children's Hospital and Medical Center of Omaha, Omaha
  • University of Nebraska Medical Center, Omaha
6 Months – 21 Years · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT04293562

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Menerima pesertaFase 1/2
  • Children's Hospital and Medical Center of Omaha, Omaha
  • University of Nebraska Medical Center, Omaha
Hingga usia 22 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04726241

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Menerima pesertaFase 1
  • University of Nebraska Medical Center, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT06001788

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Menerima pesertaFase 2/3
  • University of Nebraska Medical Center, Omaha
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06788756

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Menerima pesertaStudi observasional
  • University of Nebraska Medical Center, Omaha
Semua usia · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT01351545

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Menerima pesertaFase 1/2
  • Nebraska Cancer Specialists, Omaha
  • University of Nebraska Medical Center, Omaha
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Jun 2026 · NCT04068597

Uji klinis Leukemia Mieloid Akut di kota lain

Studi lain di Omaha

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.